Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
deals
4
×
national blog main
national top stories
4
×
startups
life sciences
vc
biotech
boston blog main
boston top stories
medical radioisotopes
new york blog main
new york top stories
radioisotopes
san francisco blog main
san francisco top stories
shine medical technologies
wisconsin
wisconsin blog main
wisconsin top stories
alphabet
azacitidine
beta-thalassemia
boston
bram daelemans
broad institute of harvard and mit
brook byers
charles chu
connecture
crispr
crispr cas14
dacogen
decheng capital
decitabine
deerfield management
diagnostic
dna
epigenetics
epizyme
evan sengbusch
farydak
What
based
4
×
deal
janesville
medical
shine
technologies
wi
according
add
aims
announced
approach
available
big
biggest
bio
biosciences
biotech
called
capital
cas
cheaper
company
council
crispr
debuts
decade
deerfield
details
develop
developing
diagnostics
didn’t
domestic
drugs
epigenetic
epigenetics
expects
familiar
faster
Language
unset
Current search:
deals
×
based
×
" national top stories "
×
@xconomy.com
4 years ago
With $45M, Mammoth Bio Expects Big Things From Tiny CRISPR Cas14
@xconomy.com
4 years ago
Flagship’s Omega Aims to Take Epigenetic Drugs a Step Further
@xconomy.com
5 years ago
Shine Raises $30M, Could Add $150M More After Inking Deerfield Deal
@xconomy.com
5 years ago
The Biggest Wisconsin Venture Round of the Decade… Didn’t Happen
